During a U.S. House of Representatives hearing on Tuesday, Richard Nettles, Vice President of Medical Affairs at J&J unit Janssen Pharmaceutical, said the company expects to deliver 20 million doses of its vaccine in the U.S. by the end of March.
During a U.S. House of Representatives hearing on Tuesday, Richard Nettles, Vice President of Medical Affairs at J&J unit Janssen Pharmaceutical, said the company expects to deliver 20 million doses of its vaccine in the U.S. by the end of March.